India-based Dhiti Omics Technologies, a provider of precision molecular diagnostics services, has deployed the SOPHiA DDM Platform from Sophia Genetics, a cloud-native software company, to enhance its capabilities for solid tumour testing.

The SOPHiA DDM has been adopted for the Agilent SureSelect Cancer CGP application. Launched last year, the application provides comprehensive genomic profiling.

This integration is expected to improve Dhiti Omics’ ability to deliver comprehensive genomic profiling to researchers.

Dhiti Omics Technologies founder and director Sudha Rao said: “Our team at Dhiti Omics is passionate about furthering the use of precision medicine and ensuring people in India and throughout the world have access to testing for better health outcomes.

“Combining high-quality reagents, and powerful analytics into one unique workflow will help us maximise insights from comprehensive genomic profiling data. This will ensure we’re delivering the fastest and most accurate diagnostics to our customer base.”

The SOPHiA DDM for SureSelect CGP application merges Agilent's genomic profiling assay kit with the SOPHiA DDM Platform.

The SOPHiA DDM AI Platform offers an integrated solution for rapid and precise insights based on the latest guidelines, which include relevant biomarkers for solid tumours.

By analysing complex genomic and multimodal data, the platform can generate real-time actionable insights and is expected to benefit a broad network of hospitals, laboratories, and biopharmaceutical institutions globally.

Sophia Genetics LAPAC managing director Ricardo Mendonca Filho said: “Our Platform and applications are designed to enable companies like Dhiti Omics to more easily advance precision medicine.

“By using SOPHiA DDM, Dhiti Omics can ensure speed and accuracy of solid tumour testing to best support the Indian population.”

Last year, Unipath Specialty Laboratory selected the SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution.